Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patient...
Upcoming SlideShare
Loading in …5
×

Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patients with bone metastases (BM) from castration-resistant prostate cancer (CRPC) Sweden, Switzerland and Portugal.

319
-1

Published on

Lothgren M, Bracco A, Lundkvist J, Biteeva I, Schwenkglenks M, Cristino J, Pereira J, Northridge K, Halperin M, Macarios D, Chung K, Danese MD. Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patients with bone metastases (BM) from castration-resistant prostate cancer (CRPC) Sweden, Switzerland and Portugal. Presented at the 9th Annual HTAi meeting 2012 (Spain Bilbao 25-27 June 2012). Abstract published in Gaceta Sanitaria 2012, Vol. 26 Especial Congreso 2 – Junio 2012: 282.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
319
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

×